Switching from injectable treprostinil or epoprostenol to a combination therapy including inhaled treprostinil appears to be safe, well…
Articles by Ana Pena, PhD
Liquidia Technologies is requesting U.S. Food and Drug Administration (FDA) approval of LIQ861, an inhaled dry…
AI Therapeutics is seeking to advance the development of its candidate treatment LAM-001 for patients with lymphangioleiomyomatosis (LAM)…
Melatonin, a natural hormone involved in sleep and believed to protect against cardiovascular diseases, may help to relieve the…
Actelion Pharmaceuticals has withdrawn all ongoing worldwide requests for expanded approval of Opsumit (macitentan),…
Bellerophon reached its enrollment goal for the second group of patients in its ongoing Phase 2/3 trial evaluating different…
Interleukin-17 (IL-17), a proinflammatory protein, appears to play important roles in the development of hypoxic pulmonary hypertension (HPH), a…
Into the vein (intravenous) injections of Revatio (sildenafil) have no added benefit over inhaled nitric oxide (iNO) used…
A combination of measures of clinical worsening may be meaningful in determining response to therapies in pediatric clinical trials, and…
A new analysis of Actelion‘s GRIPHON clinical trial indicates that Uptravi (selexipag) tablets reduce the risk of disease complications…
Bellerophon released an update on the latest data regarding its INOpulse therapy, and announced its plans to apply for…
A natural component of milk thistle seeds called silibinin…